JPRN-UMIN000008055已完成3 期
Sub-study on genetic markers responsible to effects of HMG-CoA reductase inhibitor preventing recurrence of stroke - J-STARS Genomics
Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences0 个研究点目标入组 1,000 人开始时间: 2012年6月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 45years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A research that investigates the genetic factors for the idiopathic pulmonary pneumonias (IIPs) with the subjects that have been enrolled in the multi-institutional observational study for the IIPs, NEJ030.Idiopathic pulmonary pneumoniaJPRN-UMIN000032117Jichi Medical University400
招募中
不适用
A two parts, biomarker study to identify genetic aberrations predictive for response on Everolimus in solid tumors without regular treatment options (CPCT*03)regular therapy refractory cancer10027655NL-OMON40040Antoni van Leeuwenhoek Ziekenhuis80
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
尚未招募
不适用
Heritability in Oropharynx CancerCTRI/2019/07/020299Department of Health Research